Amgen Inc. (amgn)
AMGN — Company Overview
Investors tracking AMGN follow a Drug Manufacturers - General name listed on NMS within Healthcare.
| Ticker | AMGN |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NMS |
| Market cap | $219.55B |
| Last price | $406.09 |
| Size category | Mega Cap |
AMGN — Business Description
The business profile of Amgen Inc. (AMGN) reflects its role in Drug Manufacturers - General. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a…
Official website: https://www.amgen.com.
AMGN — Investment Thesis
Amgen Inc. (AMGN) attracts investors weighing Drug Manufacturers - General fundamentals against current market pricing.
- Revenue is expanding at roughly 9.5% year-over-year (public data).
- Trailing P/E of 25.51× sits in a moderate band relative to high-growth peers.
- Forward P/E (16.62×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 2.5% adds an income component to total return.
- Equity market capitalization is approximately $219.55B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
AMGN — Financial Health
AMGN financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin of 23.0% indicates solid bottom-line conversion. Positive free cash flow of $8.65B supports balance-sheet flexibility. Debt-to-equity of 490.28 warrants monitoring in a higher-rate environment.
| Trailing P/E | 25.51× |
| Forward P/E | 16.62× |
| Price / Sales | 5.76× |
| Price / Book | 18.78× |
| Gross margin | 71.9% |
| Operating margin | 35.5% |
| Profit margin | 23.0% |
| Return on equity | 91.5% |
| Debt / Equity | 490.28 |
| Free cash flow | $8.65B |
AMGN — Growth Outlook
Growth outlook for Amgen Inc. (AMGN) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 9.5% suggests steady but measured expansion.
- Earnings growth of 64.9% year-over-year supports improving profitability.
- Price is 9.2% below the 52-week high.
AMGN — Competitive Position
Amgen Inc. (AMGN) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - General.
- Market capitalization of $219.55B places AMGN among mega-cap peers.
- Gross margin near 71.9% may reflect pricing power or favorable mix.
AMGN — Strengths
Strengths for Amgen Inc. (AMGN) inferred from public financial metrics:
- Revenue growth of 9.5% year-over-year.
- Earnings growth of 64.9% year-over-year.
- Return on equity near 91.5% — efficient use of shareholder capital.
- Gross margin of 71.9% supports competitive unit economics.
- Positive free cash flow ($8.65B).
- Dividend yield of 2.5% for income-oriented holders.
AMGN — Weaknesses
Weaknesses and pressure points for Amgen Inc. (AMGN) based on available data:
- Elevated debt-to-equity (490.28).
AMGN — Opportunities
- Sustained revenue growth (9.5%) could support multiple expansion if margins hold.
- Dividend yield of 2.5% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
AMGN — Risks
- Leverage (debt/equity 490.28) raises sensitivity to credit conditions.
AMGN — Summary
Amgen Inc. (AMGN) is a mega-cap Healthcare company focused on Drug Manufacturers - General, listed on NMS. Last price $406.09 with market cap $219.55B. Trailing P/E 25.51×. Revenue grew 9.5% year-over-year per public data. Notable strengths include revenue growth of 9.5% year-over-year. Key watch items include elevated debt-to-equity (490.28). Review free estimates and earnings pages for AMGN; upgrade for institutional ownership and live headlines.
Start Free — open AMGN in Vest Terminal
Access live data, filings, ownership, and analysis for Amgen Inc..
Amgen Inc. FAQ
What does Amgen Inc. (AMGN) do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque p…
What is AMGN's P/E ratio?
Amgen Inc. has a trailing P/E of 25.51× based on publicly available market data.
Does AMGN pay a dividend?
Indicated dividend yield: 2.5%. Confirm ex-dates and payout history in Vest Terminal.
What sector is AMGN in?
Amgen Inc. is classified in Healthcare (Drug Manufacturers - General) on NMS.
What is AMGN's market capitalization?
Approximate market cap: $219.55B.
What are the main risks for AMGN?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of AMGN?
Potential positives include revenue growth of 9.5% year-over-year, earnings growth of 64.9% year-over-year.
Where can I get analyst estimates for AMGN?
Public analyst price targets and consensus for Amgen Inc. are on the free /stocks/amgn/estimates page. Deeper estimate history and models are available in Vest Terminal.